J.P. Morgan analyst Brian Cheng has maintained their bullish stance on KYTX stock, giving a Buy rating on August 29.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brian Cheng has given his Buy rating due to a combination of factors surrounding Kyverna Therapeutics, Inc.’s strategic developments and promising clinical trial data. The company recently unveiled a strategic plan for its KVY-101 program, targeting conditions like stiff person syndrome (SPS) and myasthenia gravis (MG). The long-term data showing remission for up to two years in these conditions highlights the potential differentiation of KVY-101 in the current treatment landscape, which is a significant factor in Cheng’s positive outlook.
Moreover, the upcoming Phase 3 trial for MG, which is over 90% powered to demonstrate superiority over the standard of care, is another critical element supporting the Buy rating. The trial’s design, including its washout requirements, is expected to better define the contribution of KVY-101, potentially unlocking attractive value over the next 12 to 24 months. Additionally, the ongoing KYSA-8 trial in SPS is anticipated to show significant improvement, further underpinning the company’s market opportunities and Cheng’s optimistic assessment.
In another report released on August 29, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.